文献速递乳腺癌放疗

Cicaderma®在乳腺癌放射性皮炎中的应用:多中心随机III期CICA-RT研究结果

Cicaderma® in radiation-related dermatitis of breast cancer: Results from the multicentric randomised phase III CICA-RT.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-06-01

这项前瞻性随机开放标签多中心研究纳入258例接受术后放疗的非转移性乳腺癌患者,比较Cicaderma®与局部标准管理预防≥2级放射性皮炎的效果。主要终点未达到优效性,但Cicaderma®组瘙痒≥2级发生率显著低于标准管理组(31% vs 47%,p=0.009)。

要点

  • Cicaderma®在预防≥2级放射性皮炎方面未优于常规皮肤护理。
  • Cicaderma®组至少一次≥2级瘙痒报告率31%,标准管理组47%,p=0.009。
  • 敏感性和符合方案分析均确认两组间无差异。

核心结论

  • 这项前瞻性研究未达到Cicaderma®在预防≥2级急性放射性皮炎方面优于常规皮肤护理的主要优效性终点。
  • Cicaderma®显著降低瘙痒发生率,报告至少一次≥2级瘙痒的患者更少(A组38例,31%;B组58例,47%;p=0.009)。

研究设计与样本

  • 前瞻性随机开放标签多中心研究,从3家法国机构分配患者。
  • 纳入≥18岁、需术后放疗的组织学证实早期(非转移性)单侧乳腺腺癌或原位乳腺癌、术后R0或R1状态患者。
  • 患者接受卫生规则联合Cicaderma®(A组)或根据研究者偏好选择的预防性治疗(主要为透明质酸、精油、水喷雾或无药物)(B组)。
  • 主要结局为比较Cicaderma®与局部标准管理预防≥2级放射性皮炎发生的疗效。
  • CICA-RT研究于2020年6月至2021年4月入组258例女性,中位年龄61(22-91)岁,来自3家机构;A组130例,B组128例。

主要发现

  • 每个臂各有123例患者开始放疗,其中95例(77%,95%CI 68.8%-84.3%)未发生≥2级皮炎。
  • 敏感性和符合方案分析确认两组间无差异。
  • Cicaderma®组报告至少一次≥2级瘙痒38例(31%),标准管理组58例(47%),p=0.009。

关键数值与推荐

  • 主要终点为预防≥2级放射性皮炎发生的疗效比较。
  • 主要次要目标包括Cicaderma®对放疗中断、皮肤毒性(瘙痒)、疼痛、生活质量、满意度的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To prevent the occurrence of grade ≥ 2 radiodermatitis after post-operative breast irradiation in patients with non metastatic breast cancer. METHODS: This prospective randomised open-label multicenter study allocated patients from 3 French institutions, ≥18 years, requiring postoperative radiotherapy for histologically proven, early-stage (non-metastatic) unilateral breast adenocarcinoma or in situ breast cancer, with R0 or R1 post-operative status, to receive hygiene rules, associated with either Cicaderma® (Arm A), or preventive treatment according to the investigator preference (mainly hyaluronic acid (ialuset®), essential oils, or water spray, or no medication (Arm B). The primary outcome was to compare the efficacy of Cicaderma® versus local standard management in preventing the occurrence of grade ≥ 2 radiodermatitis. Main secondary objectives include Cicaderma® impact on radiotherapy discontinuation and on skin toxicity (pruritus), pain, quality of life, satisfaction. RESULTS: The CICA-RT study enrolled from June 2020 to April 2021, 258 women with a median age of 61 (22-91) years in 3 institutions. Patients received either Cicaderma® (A: N = 130) or standard practice (B: N = 128). In the 123 patients who initiated radiotherapy in each arm, 95 (77%, 95%CI 68.8%-84.3%) patients did not develop grade ≥ 2 dermatitis. Sensitivity and per-protocol analyses confirmed the absence of differences between arms. CONCLUSION: This prospective study did not meet its primary endpoint of superiority of Cicaderma® over routine practice skin care in terms of prevention of acute radioinduced dermatitis of grade 2 or higher. However, Cicaderma® showed a significant decrease in the occurrence of pruritus with less patients reporting at least once grade ≥ 2 pruritus (A: N = 38, 31%; B: N = 58, 47%; p = 0.009).ClinicalTrials.gov identifier NCT04300829.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Racadot S, Arnaud A, Schiffler C, et al. Cicaderma® in radiation-related dermatitis of breast cancer: Results from the multicentric randomised phase III CICA-RT. Clin Transl Radiat Oncol. 2023. PMID: 37441546. doi:10.1016/j.ctro.2023.100647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。